Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF C
obligations may continue. See	

CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol Twist Bioscience Corp [TWST]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Banyai William					Twist Dioscience Corp [1 ws1]									X Direc	tor	10)% Ow	ner		
(Last)	(Fir	,	⁄iiddle)		3. Date of Earliest Transaction (Month/Day/Year) 09/05/2023								X Office below	,	be	ther (s	pecify			
C/O TWIST BIOSCIENCE CORPORATION														See Remarks						
681 GATEWAY BLVD.					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)															X Form filed by One Reporting Person					
SOUTH SAN FRANCISCO CA 94080														Form filed by More than One Reporting Person						
					Rule 10b5-1(c) Transaction Indication															
(City)	(Sta	ate) (2	Ľip)			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				y/Year) Exec		Deemed ecution Date, ny onth/Day/Year)					es Acquired (A) Of (D) (Instr. 3,			Benefi Owned	ties cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	ct c ect E	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A (C	A) or O)	Price		ea ction(s) 3 and 4)			(Instr. 4)	
Common Stock 09/05/					/2023				A 25,000 ⁽¹⁾		1)	Α	\$0	0 293,513		D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date,			4. Transaction Code (Instr. 8)		mber vative crities cired r osed) r. 3, 4	Expirati	ate Exercisable and iration Date nth/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		f g	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Securities Owned Following Reported Transactio (Instr. 4)	Owne Form Direct or Ind (I) (Ins	(D) irect	Beneficial Ownership (Instr. 4)	
					Code V		(A)	(D)	Date Exercis	able	Expiration Date	Amou or Numb of Title Share		nber						

Explanation of Responses:

1. Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of September 25, 2023 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date.

Senior Vice President of Advanced Development and General Manager of Data Storage

/s/ Alyssa Zhang, as Attorney-09/07/2023 in-Fact for William Banyai ** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.